OPAL Fuels Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that OPAL Fuels Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $348.98M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $299.97M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $256.11M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $235.53M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $166.12M | Mar 29, 2023 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $326.72M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $290.86M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $251.15M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $230.66M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $162.05M | Mar 29, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | ($16.19M) | Mar 9, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.41M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $21.22M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $7.04M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $7.56M | Mar 15, 2024 |
| FY2021 | Dec 31, 2021 | ($4.94M) | Mar 9, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.94M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $19.11M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $4.87M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $6.44M | Mar 15, 2024 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $63.98M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $53.12M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $51.26M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $51.39M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $29.38M | Mar 29, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.50M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $31.39M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $38.27M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($1.36M) | Mar 15, 2024 |
| FY2021 | Dec 31, 2021 | ($1.94M) | Mar 9, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $70.74M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $127.24M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $113.83M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $131.41M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $89.65M | Mar 29, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $959.47M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $881.08M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $754.61M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $644.86M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $380.84M | Mar 29, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $461.71M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $416.05M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $297.12M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $267.04M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $285.89M | Mar 29, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.93M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($148.45M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($478.81M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($800.60M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $14.0K | Mar 29, 2023 |
| FY2021 | Jan 12, 2021 | $0 | Mar 9, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $54.61M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $54.61M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $54.61M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $54.61M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $54.61M | Mar 29, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.31M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($137.00M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($467.20M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($800.81M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 29, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.41M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $24.31M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $38.35M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $40.39M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $39.31M | Mar 29, 2023 |
| FY2021 | Jan 12, 2021 | $0 | Mar 9, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $361.27M | Mar 16, 2026 |
| FY2024 | Dec 31, 2024 | $307.46M | Mar 17, 2025 |
| FY2023 | Dec 31, 2023 | $209.07M | Mar 15, 2024 |
| FY2022 | Dec 31, 2022 | $170.44M | Mar 29, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 29, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 29, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Jul 21, 2022 | 170.07M | Mar 29, 2023 |
| FY2022 | Jul 20, 2022 | 25.67M | Mar 29, 2023 |